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Bone formation and remodeling involves production of 
bone matrix by osteoblasts and its resorption by osteoclasts. 
Increased osteoclast activity or reduced osteoblast function 
leads to osteopenic disorders (Kong et al., 1999). Therefore, 
it is crucial to understand mechanisms underlying osteoclast 
regulation. Such understanding will shed light on identify-
ing potential therapeutic targets of osteoporosis, a disease 
caused by too much bone resorption or insufficient bone 
formation. RANKL-RANK signaling is required for osteo-
clast, activating a variety of downstream signaling path-
ways. RANK, also known as tumor necrosis factor (TNF) 
superfamily member 11 (TNFSF11), has long been consid-
ered to be the sole receptor for RANKL, also known as 
TNFRSF11A, (Hanada et al., 2011). In a recent study, 
Mingyao Liu and Jian Luo, Jianru Xiao, et al., at East China 
Normal University, have discovered that the leucine-rich 
repeat-containing G-protein-coupled receptor 4 (LGR4, also 
called GPR48) is a novel receptor for RANKL, in that it 
competes with RANK for RANKL binding in osteoclasts, 
and that it negatively regulates osteoclast differentiation and 
bone remodeling (Luo et al., 2016). This research, published 
in Nature Medicine, provides the first evidence that a 
RANKL-LGR4-Gαq-GSK3-β-NFATC1 signaling pathway 
regulates osteoclastogenesis and suggests that LGR4 is a 
candidate for treating osteoporosis and other bone-     
resorption diseases. This finding provides a molecular 
mechanism explanation to the low bone density of LGR4- 
deficiency in humans and mice, as well as to many other 
potential defects caused by LGR4 mutation. 
The Tnfsf11−/− mice exhibit the osteopetrosis phenotype 
caused by reduced bone resorption, and it also showed dis-
rupted immune regulation, and failure of mammary gland 
lobuloalveolar development. Liu’s team noticed that the 
Lgr4−/− mice shared some similar sets of phenotypes with 
the Tnfsf11−/− mice, thus suggesting that LGR4 lies in the 
same pathway as RANKL-RANK (Luo et al., 2016). This 
team then demonstrated, with rigorous biochemical assays, 
that RANKL directly binds human LGR4, but that RANK 
doesn’t bind LGR4. The team further showed that the ex-
tracellular domain (ECD) of LGR4 mediates the specific 
interaction between LGR4 and RANKL.  
G-protein-coupled receptors (GPCRs or GPRs) are inte-
gral membrane proteins involved in the transmission of 
signals from the extracellular environment to the cytoplasm. 
GPCRs are important drug targets. Predicted to be a G pro-
tein-coupled receptor (GPCR), LGR4 is also associated with 
Wnt receptors and it mediates R-spondin signaling. 
R-spondins (RSPOs) have been reported as functional lig-
ands for LGR4 in adult stem cell maintenance and activity. 
RSPO binding to LGR4 only activates Wnt signaling. 
Therefore, additional LGR4 ligands are responsible for the 
activation of G-protein signaling pathways downstream of 
LGR4 which are implicated in eye development, innate 
immunity, energy expenditure, and osteoblast differentia-
tion. This is so, even though previous studies showed that 
the ligands of LGR4 failed to activate heterotrimeric 
G-proteins to transduce the signal (Carmon et al., 2011). 
Interestingly, the authors found that LGR4 activates Gαq 
when binding with RANKL and induces intracellular cal-
cium release. This is the first report showing G-protein sig-
naling can be induced via ligand activated LGR4.  
Similar to RANKL, LGR4 is shown to regulate osteo-
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clast differentiation. By analyzing bone phenotypes of two 
mutant mice lines-whole-body (Lgr4−/−) and monocyte con-
ditional mutant mice of Lgr4 (Lgr4 CKO)- the authors 
found that hyperactivation of osteoclasts, as shown by 
greater numbers of TRAP-positive osteoclasts and larger 
osteoclast size in the femoral bones and calvaria bones in 
vivo. Further more, the authors also provided in vitro evi-
dences that loss of Lgr4 in the bone marrow monocytes 
(BMMs) from Lgr4 CKO mice enhances the formation of 
osteoclast and accelerates BMMs differentiation when 
treated with RANKL. In addition, LGR4 also regulates os-
teoclast survival by inducing apoptosis. The authors’ find-
ing mechanically explained the phenomenon that the mature 
osteoclasts finally undergo apoptosis even in an environ-
ment with RANKL. 
In osteoblasts, Lgr4 appears to have a different function. 
Liu’s team showed that Lgr4 acts through the cAMP-PKA- 
CREB pathway to regulate the expression level of Atf4 in 
osteoblasts, showing that Lgr4 is involved in the osteoblast 
differentiation and bone formation (Luo et al., 2009). Com-
pared with its function in the osteoclastogenesis, they do 
suggest that the osteoclast deficiency is the major cause of 
low bone mass seen in mice and humans with an LGR4 
mutation. 
RSPOs and Norrin are the ligands of LGR4. The authors 
found that RSPOs and Norrin are not involved in Lgr4-  
deficiency-induced osteoclastogenesis. Instead, LGR4 reg-
ulates canonical RANKL-RANK signaling through: (i) 
LGR4-ECD competes with RANK to bind with RANKL, 
(ii) LGR4 decreases interaction between RANK and a 
downstream component TRAF6, (iii) LGR4 abrogated 
RANKL- induced NF-κB signaling. 
The transcription factor NFATC1 is a master regulator of 
RANKL-induced osteoclastogenesis, when NFATC1 is ex-
pressed in precursor cells. By overexpression of a constitu-
tively active form of Gαq (GαqCA), the authors showed that 
GαqCA blocked Lgr4-knock-down-induced osteoclast dif-
ferentiation via decreasing phosphorylation of glycogen 
synthase kinase 3-β (GSK3-β). GSK3-β phosphorylation  
inhibits GSK3-β activity that promotes NFATC1nuclear 
localization. These observations led to the identification of a 
new RANKL-LGR4-Gαq-GSK3-β-NFATC1 pathway in 
osteoclastogenesis. They also demonstrated that LGR4 ex-
pression is induced by RANKL-NFATC1 signaling during 
osteoclast differentiation, thus indicating a negative-feed- 
back mechanism exists to limit osteoclastogenesis.  
The soluble LGR4-ECD protein might be used to treat 
osteoporosis as it can block osteoclast differentiation in-
duced by RANKL. The authors showed that in ovariectomy, 
RANKL injected and Tnfrsf11b-deficient osteoporosis 
mouse models, treated with LGR4-ECD, increased bone 
mass, but LGR4-ECD protein had little effect on osteoclast 
differentiation in wild type mice. A mechanistic under-
standing of RANKl-LGR4 interaction has provided new 
insight into LGR4 mediated RANKL signaling in osteopo-
rosis and other diseases. 
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